je.st
news
Tag: vaccine
Drugmakers to join forces to make millions of Ebola vaccine doses
2014-10-22 19:08:21| Biotech - Topix.net
Leading drugmakers plan to work together to speed up the development of an Ebola vaccine and hope to produce millions of doses for use next year. U.S. firm Johnson & Johnson said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain's GlaxoSmithKline, which is working on a rival vaccine.
Tags: make
join
forces
millions
J&J aims for 1 million Ebola vaccine doses in 2015
2014-10-22 12:50:35| Food - Topix.net
Johnson & Johnson is accelerating work on its experimental Ebola vaccine and said on Wednesday that it aims to have 1 million doses ready in 2015, of which 250,000 are expected to be available by May. There is currently no proven vaccine against the deadly disease but several companies are racing to develop products and clinical tests on two - from GlaxoSmithKline and NewLink Genetics - are already under way. The World Health Organization hopes that tens of thousands of people in West Africa, including frontline healthcare workers at high risk of infection, can start receiving Ebola vaccines from January as part of large-scale clinical trials.
US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteurs Investigational Pediatric Hexavalent Vaccine
2014-10-20 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & SWIFTWATER, Pa. Phase III clinical study data presented at IDWeek in Philadelphia WHITEHOUSE STATION, N.J. & SWIFTWATER, Pa.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License Application (BLA) filed for the companies investigational pediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB1, has been accepted for review by the U.S. Food and Drug Administration (FDA). Language: English Contact: MerckMedia:Deb Wambold, (215) 652-2913orInvestors:Justin Holko, (908) 423-5088orSanofi PasteurMedia:Susan Watkins, (570) 957-2563susan.watkins@sanofipasteur.comorInvestors:George Grofik, (908) 981-5560IR@sanofi.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: SAN Exchange: BOURSE Ticker: SNY Exchange: NYSE read more
Tags: review
application
license
accepts
Ebola Vaccine Push Ramps Up
2014-10-20 08:27:39| Biotech - Topix.net
Nancy Sullivan, who developed the first Ebola vaccine effective in monkeys that now has begun preliminary human testing, talks with colleague Sabue Mulangu at her lab at the National Institutes of Health on Friday. BETHESDA, Md.-The world had little interest in Ebola in 1997, which is why cell biologist Nancy J. Sullivan thought she might be able to make a mark.
Tags: push
vaccine
ramps
ebola
How will we develop an Ebola vaccine, and when will it be ready?
2014-10-16 15:52:15| Extremetech
Ebola is a deadly virus that kills 60-90 percent of the humans it infects. After a brief incubation period, the virus begins damaging the blood vessels, leading to massive internal bleeding and typically, circulatory shock. As the largest Ebola outbreak ever recorded now bleeds unchecked out of Africa and into the West, the question on everyone's lips is, "when will we make a vaccine"?
Sites : [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] next »